At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Ixabepilone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
In Brief
A Phase 2 clinical trial evaluating Ixabepilone and Laboratory Biomarker Analysis for Recurrent Uterine Corpus Sarcoma and Uterine Carcinosarcoma. Completed, enrolled 42 participants across 78 sites.
Detailed Summary
This phase II trial is studying the side effects and how well ixabepilone works in treating patients with persistent or recurrent uterine cancer. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNRG Oncology
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartSep 2010
Primary CompletionNov 2013
TodayJul 2026
First PostedJul 23, 2010
Enrollment StartSep 7, 2010
Primary CompletionNov 26, 2013
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 15.9 years ago
Interventions
Ixabepilonedrug
Given IV
Laboratory Biomarker Analysisother
Correlative studies